Arash Mostaghimi is a Dermatologist in Boston, Massachusetts. Mostaghimi has been practicing medicine for over 16 years and is rated as an Elite expert by MediFind in the treatment of Alopecia Totalis. He is also highly rated in 39 other conditions, according to our data. His top areas of expertise are Alopecia Totalis, Alopecia Areata, Autosomal Recessive Hypotrichosis, and Alopecia Universalis. Mostaghimi is currently accepting new patients.
Brett King is a Dermatologist in Middlebury, Connecticut. King has been practicing medicine for over 18 years and is rated as an Elite expert by MediFind in the treatment of Alopecia Totalis. He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Alopecia Totalis, and Alopecia Universalis. King is currently accepting new patients.
Julian Mackay-Wiggan is a Dermatologist in Boynton Beach, Florida. Mackay-Wiggan has been practicing medicine for over 25 years and is rated as an Elite expert by MediFind in the treatment of Alopecia Totalis. She is also highly rated in 9 other conditions, according to our data. Her top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Alopecia Totalis, and Alopecia Universalis.
Summary: Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.5 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% to 0.2% and calculated lifetime risk of 2%. AA is the most common form of the disease, in which areas of complete hair loss arise within normal hair-bear...
Summary: The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center